RIO DE JANEIRO, BRAZIL - The vaccination campaign against Covid-19 in Brazil began last week, after the emergency use approval by the National Health Regulatory Agency (ANVISA) of two vaccines: CoronaVac, from the Butantan Institute, and the Oxford-AstraZeneca, supplied by Fiocruz.
Immunization is still restricted to a small portion of priority groups, including front-line health professionals, elderly people living in long-term institutions, and indigenous villagers.
The reasons for this are the emergency use authorization itself and the limited vaccine supply. Emergency use authorization is temporary and its administration is limited to certain population groups. However, low supply . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here